Clinical Updates
Grave’s orbitopathy – an approach to clinical evaluation and management
Authors:
TWN Karunasena ,
Colombo South Teaching Hospital, Kalubowila, LK
MWS Niranjala
Teaching Hospital, Anuradhapura,, LK
Abstract
Grave’s orbitopathy (GO), is a potentially sight threatening condition which constitutes a major clinical and therapeutic challenge and occurs in about 50% of patients with Grave’s disease with only 3-5% cases posing threat to sight. This autoimmune condition is mediated via cytokines secreted by T lymphocytes infiltrating in to the orbital cavity and thyrotropin receptor antibodies (TRAbs) stimulating thyrotropin receptors (TSHR). Clinical assessment for disease activity and severity in GO is important for decision making in management of both hyperthyroidism and GO. Sight threatening GO should be identified promptly and treated with high dose intravenous (IV) glucocorticoids and/or orbital decompression.
Sri Lanka Journal of Diabetes, Endocrinology and Metabolism 2012; 2: 106-110
DOI:
http://dx.doi.org/10.4038/sjdem.v2i2.4781
How to Cite:
Karunasena, T. and Niranjala, M., 2012. Grave’s orbitopathy – an approach to clinical evaluation and management. Sri Lanka Journal of Diabetes Endocrinology and Metabolism, 2(2), pp.106–110. DOI: http://doi.org/10.4038/sjdem.v2i2.4781
Published on
18 Oct 2012.
Peer Reviewed
Downloads
